Brief: Recce Pharmaceuticals Says HREC Approval Accelerates Global Phase 3 Dfi Strategy
22/06/2026 02:20
BRIEF-Recce Pharmaceuticals Says HREC Approval Accelerates Global Phase 3 Dfi Strategy June 22 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:
HREC APPROVAL ACCELERATES GLOBAL PHASE 3 DFI STRATEGY
Further company coverage: RCE.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Recce Pharmaceuticals
See all newsBrief: Recce Pharmaceuticals Says U.S. Government Releases $66.9B AMR Biodefense Strategy
Australia's Recce Pharmaceuticals slips to near 11-month low on discounted placement
Brief: Recce Pharmaceuticals Raises A$4 Million Via Institutional Placement
Brief: Recce Pharmaceuticals Requests Trading Halt Pending Announcement On Proposed Equity Capital Raise
Brief: Recce Pharmaceuticals Says HREC Approval Accelerates Global Phase 3 Dfi Strategy